ResMed (RMD) Q3 2026 Earnings Transcript

ResMed posted strong Q3 results with revenue up 11% to $1.43 billion, gross margin expanding 290 bps to 62.8%, and non-GAAP EPS rising 21%. Free cash flow reached $520 million, and the company returned $262 million to shareholders while reaffirming 2026 margins and tax guidance. Management also announced a $340 million acquisition of Noctrix Health, signaling continued portfolio expansion in sleep-health devices and adjacent therapy markets.

Analysis

RMD is compounding into a rarer setup: revenue is still mid/high-single-digit despite a mature category, while margin expansion is now being driven by mix, supply chain normalization, and pricing discipline rather than just cyclical recovery. That matters because it suggests the earnings model is becoming less sensitive to transient freight/component swings and more sensitive to durable product-cycle share gains, especially in premium masks and connected devices. The real second-order read is that the company is using superior free cash flow to finance both innovation and M&A without sacrificing capital returns, which should keep valuation support intact.

The GLP-1 angle is underappreciated. Even if the direct patient overlap is not huge in the near term, pharma advertising is acting as a demand-generation subsidy for sleep apnea diagnosis and PAP initiation, which benefits RMD’s ecosystem more than any single product line. The key operating leverage is not the prescription itself; it is the higher downstream resupply, adherence, and channel throughput that can lift lifetime value across masks, accessories, and home testing. If this behavior persists for 4-8 quarters, it can offset reimbursement pressure and any competitive noise better than consensus expects.

Noctrix is strategically sensible but financially modest near-term: it is a higher-growth, higher-margin adjacency that broadens RMD’s control over sleep physicians and HME channels, but the small dilution in Q4 likely masks a larger medium-term option value if reimbursement expands. The main risk is not execution on this deal; it is over-extrapolation of current operating momentum into a straight line. The most realistic bear case is a mix of payer utilization management, price pressure on premium masks, and a normalization of FX/supply-chain tailwinds, which could cap multiple expansion even if fundamentals remain solid.

Key Decisions for Investors

• Long RMD vs. short UNH for 3-6 months: RMD has a clearer path to operating leverage from demand generation and product mix, while UNH faces greater policy/utilization-management headline risk. Use a 2:1 upside/downside frame; trim if RMD rerates above historical premium before the next quarterly print.
• Buy RMD shares on any 3-5% post-earnings pullback over the next 2-4 weeks: near-term catalysts include Noctrix close, buyback execution, and continued gross margin upside. Risk/reward remains favorable as long as gross margin holds above 62% and U.S. device growth stays at or above mid-single digits.
• Add a 6-12 month RMD call spread rather than outright equity for convexity to GLP-1-driven demand and mask share gains: the thesis is that the market underestimates sustained resupply acceleration, but valuation compression is the main risk if rates stay elevated.
• Pair long RMD / short a med-tech laggard with less organic growth and weaker cash conversion, such as BAX, on a 6-month horizon: RMD’s FCF conversion and buyback support should outperform if healthcare multiples stay range-bound.
• Watch for a sell-the-news opportunity if Noctrix integration commentary turns promotional but EPS dilution is unchanged: if the stock prices in the full strategic value before reimbursement data improve, take partial profits and wait for evidence of accretion.